{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:10:08Z","timestamp":1792469408068,"version":"4.5.0"},"reference-count":32,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Fixed-duration venetoclax plus rituximab (VR) is a standard therapy for relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL). However, evidence supporting its use after covalent BTK inhibitor (c-BTKi) therapy is scarce in clinical trials and limited in real-world settings. Objectives: To assess the efficacy and safety of VR in a real-world cohort of patients with R\/R CLL, including cBTKi-pretreated individuals, and to contextualize outcomes alongside published real-world studies and registrational trials of alternative therapies. Methods: We retrospectively analyzed 37 patients with R\/R CLL treated with VR at our center between April 2018 and November 2024. Baseline characteristics, treatment responses, minimal residual disease (MRD), and adverse events were recorded. Survival was estimated using the Kaplan\u2013Meier method. A structured review of relevant real-world evidence and pirtobrutinib clinical trials was also conducted. Results: Median age was 67 years; 35.1% had prior cBTKi exposure. The overall response rate (ORR) was 91.7% (22\/24 evaluable patients), with 66.7% achieving complete remission (CR). Among evaluable c-BTKi-pretreated patients, the ORR was 87.5% (7\/8) and the CR rate was 62.5%. Undetectable MRD (uMRD) rates were 78.6% in peripheral blood and 71.4% in bone marrow. Thirty-month progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS) were &gt;90% for the whole cohort and for c-BTKi-pretreated patients. The most frequent adverse event was neutropenia grade \u2265 3, especially during combination therapy, which is easily managed with GCSF support. Conclusions: Our real-world evidence shows that VR is an effective and well-tolerated option even after c-BTKi therapy in R\/R CLL. These data complement evidence from emerging therapies and inform post-c-BTKi treatment selection in clinical practice.<\/jats:p>","DOI":"10.3390\/cancers17193159","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:40:52Z","timestamp":1759146052000},"page":"3159","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Venetoclax\u2013Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed\/Refractory CLL: A Real-World Cohort and Literature Overview"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8197-9895","authenticated-orcid":false,"given":"Maria","family":"Dimou","sequence":"first","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1219-8715","authenticated-orcid":false,"given":"Rodanthi","family":"Fioretzaki","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calliope","family":"Zerzi","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Konstantinou","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Asimakopoulos","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Arapaki","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Piperidou","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Machairas","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Kopsaftopoulou","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Liaskas","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Bitsani","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Belia","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3748-6142","authenticated-orcid":false,"given":"Fotios","family":"Panitsas","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Benekou","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Petsa","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Plata","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Tsaftaridis","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3983-4657","authenticated-orcid":false,"given":"Marina","family":"Siakantaris","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8766-1853","authenticated-orcid":false,"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis","family":"Panayiotidis","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Angelopoulou","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","article-title":"Chronic lymphocytic leukaemia","volume":"104","author":"Ferreri","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3324\/haematol.2019.236000","article-title":"Chronic lymphocytic leukemia: From molecular pathogenesis to novel therapeutic strategies","volume":"105","author":"Delgado","year":"2020","journal-title":"Haematologica"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Burger, J.A., Barr, P.M., Robak, T., Owen, C., Tedeschi, A., Sarma, A., Patten, P.E., Grosicki, S., McCarthy, H., and Offner, F. (Blood, 2025). Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment for chronic lymphocytic leukemia\/small lymphocytic lymphoma, Blood, online ahead of print.","DOI":"10.1182\/blood.2024028205"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.2024024476","article-title":"Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN","volume":"146","author":"Sharman","year":"2025","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","article-title":"Zanubrutinib Versus Bendamustine and Rituximab in Patients with Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA","volume":"43","author":"Shadman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Robrecht","year":"2024","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0140-6736(24)00595-6","article-title":"Chronic Lymphocytic Leukeia","volume":"404","author":"Jain","year":"2024","journal-title":"The Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e70064","DOI":"10.1002\/hon.70064","article-title":"Advances in the management of relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"43","author":"Davids","year":"2025","journal-title":"Hematol Oncol."},{"key":"ref_11","unstructured":"Fendrick, A.M. (2025, April 27). Real-World Evidence: An Additional Tool to Support Clinical Decision-Making. ISPOR. Available online: https:\/\/www.ispor.org\/docs\/default-source\/strategic-initiatives\/ispor-rwe-byline-article_10-25-21.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","article-title":"Real-world data: Towards achieving the achievable in cancer care","volume":"16","author":"Booth","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/cpt.1226","article-title":"Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?","volume":"105","author":"Eichler","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: An European Research Initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"},{"key":"ref_16","unstructured":"National Cancer Institute (2025, April 27). Common Terminology Criteria for Adverse Events (CTCAE) v5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"ref_17","unstructured":"European Medicines Agency (2025, April 27). Venclyxto: Summary of Product Characteristics, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/venclyxto-epar-product-information_en.pdf."},{"key":"ref_18","unstructured":"IBM Corp. (2022). IBM SPSS Statistics for Windows, Version 29.0, IBM Corp."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2025014","DOI":"10.4084\/MJHID.2025.014","article-title":"Greek Consensus on Chronic Lymphocytic Leukemia (CLL) Treatment","volume":"17","author":"Sachanas","year":"2025","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3960\/jslrt.24014","article-title":"Real-world outcomes of venetoclax and rituximab for chronic lymphocytic leukemia\/small lymphocytic lymphoma: A retrospective analysis of nine Japanese cases","volume":"64","author":"Saburi","year":"2024","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.27563","article-title":"Treatment effectiveness of venetoclax-based therapy after Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: An international real-world study","volume":"100","author":"Ghosh","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1182\/bloodadvances.2023011327","article-title":"Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon","volume":"8","author":"Lew","year":"2024","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e4428024","DOI":"10.1097\/01.HS9.0000969508.44280.24","article-title":"P651: Real-world effectiveness of venetoclax-based regimens in patients with chronic lymphocytic leukemia in Israel: Update from the multicenter prospective REVEAL study","volume":"7","author":"Herishanu","year":"2023","journal-title":"HemaSphere"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Morrens, J., Lettens, T., Gillon, B., De Bevere, M., and Poedts, L. (2024, January 18\u201321). Real-world treatment usage of venetoclax-rituximab in relapsed\/refractory CLL patients in Belgium: Results of the AREVEDECY study. Proceedings of the ISPOR Europe 2024 Congress, Barcelona, Spain.","DOI":"10.1016\/j.jval.2024.10.092"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.1182\/blood-2024-200644","article-title":"Clinical outcomes of CLL patients treated with venetoclax under real-world conditions in Austria, Germany, and Switzerland after treatment with ibrutinib","volume":"144","author":"Schwaner","year":"2024","journal-title":"Blood"},{"key":"ref_27","unstructured":"European Medicines Agency (2025, July 13). Jaypirca (Pirtobrutinib): Summary of Product Characteristics. EMA: Amsterdam, The Netherlands, Available online: https:\/\/www.ema.europa.eu."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Woyach, J.A., Brown, J.R., Ghia, P., Roeker, L.E., Patel, K., Eyre, T.A., Munir, T., Lech-Maranda, E., Lamanna, N., and Tam, C.S. (2023, January 9\u201312). Pirtobrutinib in post-cBTKi CLL\/SLL: ~30 months follow-up and subgroup analysis with\/without prior BCL2i from the phase 1\/2 BRUIN study. Proceedings of the 65th American Society of Hematology (ASH) Annual Meeting, San Diego, CA, USA.","DOI":"10.1182\/blood-2023-185852"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO-25-00166","article-title":"Phase III trial of pirtobrutinib versus idelalisib\/rituximab or bendamustine\/rituximab in covalent Bruton tyrosine kinase inhibitor\u2013pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321)","volume":"43","author":"Sharman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2024025525","article-title":"The MURANO study: Final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL","volume":"145","author":"Kater","year":"2025","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2024-194748","article-title":"Outcomes of therapies following discontinuation of non-covalent Bruton\u2019s tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia and Richter transformation: Results from an international, multicenter study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3159\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:55:59Z","timestamp":1759146959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":32,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17193159"],"URL":"https:\/\/doi.org\/10.3390\/cancers17193159","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]}}}